Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-12-21
2008-09-16
Carlson, Karen Cocrhane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S094640, C424S094630, C424S278100
Reexamination Certificate
active
07425534
ABSTRACT:
The present invention relates to compositions and methods comprising one or more domains of urokinase-type plasminogen activator (uPA) in an amount effective to modulate one or more of the contractility and angiogenic activity of a mammalian muscle or endothelial cell or tissue for use in the treatment of a disease or condition having as a symptom thereof one or more of abnormal muscle cell or tissue contractility and abnormal angiogenic activity. The one or more domains of uPA can be present in the inventive compositions and methods either as part of the full uPA molecule in either single chain or two chain form (scuPA or tcuPA), or as an isolated polypeptide, or a fragment of the uPA molecule (e.g., the amino terminal fragment “ATF”), or a deletion mutant of the uPA molecule. The inventive methods comprise administering to a mammal afflicted with such a disease or condition the inventive composition, and modulating one or more of the contractility and the angiogenic activity of the muscle or endothelial cell or tissue, thereby treating the disease or condition. Kits for treating such diseases are also included.
REFERENCES:
patent: 4160452 (1979-07-01), Theeuwes
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 5292750 (1994-03-01), Yoshikuni et al.
patent: 5681721 (1997-10-01), Steffens et al.
patent: 5833982 (1998-11-01), Berkner et al.
patent: 5945403 (1999-08-01), Folkman et al.
patent: 6497877 (2002-12-01), Stringer et al.
patent: 6833357 (2004-12-01), Cines et al.
patent: 2003/0113271 (2003-06-01), Katyama et al.
Poliakov et al. (2001) Plasmin-dependent elimination of the growth-factor-like domain in urokinase causes its rapid cellular uptake and degradation. Biochem. J. 355, pp. 639-645.
Ribatti et al. (1999) In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. J. Cell Sci. vol. 112, part 23, pp. 4213-4221.
Koolwijk et al. (1996) Cooperative effect of TNFalpha, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J. Cell Biol. vol. 132, No. 6, pp. 1177-1788.
Bdeir et al. (2003) The kringle stabilizes urokinase binding to the urokinase receptor. Blood. vol. 102, No. 10, pp. 3600-3608.
Mukhina et al. (2000) The chemotactic action of urokinase on smooth muscle cells is dependent on its kringle domain. Characterization of interactions and contribution to chemotaxis. J. Biol. Chem. vol. 275, No. 22, pp. 16450-16458.
Harrington et al. (2004) Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. vol. 126, pp. 513S-548S.
Goto et al. (2003) Acute intracerebroventricular administration of either carboxyl-terminal or amino-terminal fragments of agouti-related peptide produces a long-term decrease in energy expenditure in rats. Int. J. Mol. Med. vol. 12, No. 3, pp. 379-383.
NCBI Sequence Viewer 2.0 (2006) CAA01390 uPA, see http://www.ncbi.nlm.nih.gov/entrez/view.fcgi?db=protein& val=512447.
Dumler et al. (1999) Urokinase induces activation and formation of Stat4 and Stat1-Stat2 complexes in human vascular smooth muscle cells. J. Biol. Chem. vol. 274. No. 34, pp. 24059-24065.
START (2006) The challenge of mild asthma, http://hcp.pulmicort.com/article /502140.aspx, p. 1.
Franco et al. (2006) Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin. J. Cell Sci., vol. 119, part 16, pp. 3424-3434.
Winn et al. (2005) The role of endothelial cell apoptosis in inflammatory and immune diseases. J. Thromb. Haemost. vol. 3, No. 8, pp. 1815-1824.
Altschul et al., 1990, J. Mol. Biol. 215:403-410.
Altschul et al., 1997, Nucleic Acids Res. 25:3389-3402.
Bacharach et al., 1992, Proc. Natl. Acad. Sci. USA 89:10686-10690.
Bugge et al., 1996, Proc. Natl. Acad. Sci USA 93:5899-5904.
Carmeliet et al., 1994, Nature 368:419-424.
Carmeliet et al., 1996, Haemostasis 26:132-153.
Carmeliet et al., 1997, Cir. res. 81:829-839.
Carmeliet et al., 1998, J. Cell Biol. 140:233-245.
Chang et al., 1992, Br. J. Pharmacol. 107:983-989.
Clowes et al., 1990, Circ. Res. 67:61-67.
Degryse et al., 1999, Blood 94:649-662.
DePetro et al., 1994, Exp. Cell Res. 213:286-294.
Goldberg et al., eds, 1997, In: Regulation of Angiogenesis, Birkhauser Verlag, Basel, pp. 391-411.
Gurewich et al., 1987, Semin. Thromb. Hemost. 13:146-151.
Higazi et al., 1995, J. Biol. Chem. 270:17375-17380.
Higazi et al., 1996, Biochemistry 35:6884-6890.
Higazi et al., 1996, Thromb. Res. 84:243-251.
Higazi et al., 1998, Blood 92:2075-2083.
Husain, 1991, Biochemistry 30:5797-5805.
Johnsson et al., 1995, J. Mol. Recognit. 8:125-131.
Kanse et al., 1997, Arteriosclerosis, Thromb., and Vas. Biol. 17:2848-2854.
Karlin et al., 1990, Proc. Natl. Acad. Sci. USA 87:2264-2268.
Karlin et al., 1993, Proc. Natl. Acad. Sci. USA 90:5873-5877.
Kirchheimer et al., 1987, Fed. Am. Soc. of Exper. Biol. and Med. Journal 1:125-128.
Koopman et al., 1998, J. Biol. Chem. 273:33267-33272.
Linjen et al., 1998, Arterioscler. Thromb. Vasc. Biol. 18:1035-1045.
Noda-Heiny et al., 1995, Arterioscler. Thromb. Vasc. Biol. 15:37-43.
Odekon et al., 1992, J. Cell. Physiol. 150:258-263.
Oyama et al., 1986, Eur. J. Pharmacol. 131:75-78.
Pedersen et al., 1996, Br. J. Haematol. 95:45-51.
Pepper et al., 1990, J. Cell. Biol. 111:743-755.
Pinsky et al., 1998, J. Clin. Invest. 102:919-928.
Rabbani et al., 1992, J. Biol. Chem. 267:14151-14156.
Shireman et al., 1997, J. Vasc. Surg. 25:157-164.
Urano et al., 1988, Arch. Biochem. Biophys. 264:222-230.
Cines Douglas B.
Higazi Abd Al-Roof
Carlson Karen Cocrhane
Drinker Biddle & Reath LLP
Liu Samuel Wei
The Trustees of the University of Pennsylvania
LandOfFree
Compositions and methods for modulating muscle cell and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for modulating muscle cell and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for modulating muscle cell and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3991891